Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Daniel AlcoleaJordi PeguerolesLaia MuñozValle CamachoDiego López-MoraAlejandro Fernández-LeónNathalie Le BastardEls HuyckAlicia NadalVerónica OlmedoFrederic SampedroVictor MontalEduard VilaplanaJordi ClarimónRafael BlesaJuan ForteaAlberto Lleó

Published in: Annals of clinical and translational neurology (2019)

CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of Aβ1-42 with Aβ1-40 increases the agreement between markers of amyloid pathology.

Keyphrases

high resolution
computed tomography
cognitive decline
pet ct
mass spectrometry
mild cognitive impairment
photodynamic therapy
cerebral ischemia